Needham initiated coverage of BioAge Labs (BIOA) with a Buy rating and $50 price target The firm is “bullish” on the company’s lead asset BGE-102, an oral, NLRP3 inhibitor in Phase 1 development for cardiovascular risk in obese patients. BGE-102’s safety and early biomarker data demonstrate “best-in-class potential in a very large indication,” the analyst tells investors in a research note. Needham sees a favorable risk/reward for the shares ahead of several catalysts in the next 12-15 months.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOA:
- BioAge Labs: Early-Stage Promise in APJ Agonists Balanced by Execution Risk Supports Hold Rating
- BioAge Labs files automatic mixed securities shelf
- BioAge Highlights BGE-102 Progress and Financial Strength
- BIOA Earnings this Week: How Will it Perform?
- BioAge Labs price target raised to $52 from $15 at Citi